跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT00180791
NCT00180791Unknown2 期

Treatment Protocol for High-Risk PNET Brain Tumors in Children With Surgery, Sequential Chemotherapy, Conventional and High-Dose With Peripheral Blood Stem Cell Transplantation and Radiation Therapy

Gustave Roussy, Cancer Campus, Grand Paris2 个研究点 分布在 1 个国家目标入组 71 人开始时间: 2002年7月最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
相关药物

试验速览

阶段
2 期
入组人数
71
试验地点
2
主要终点
Response of medulloblastoma metastases to the chemotherapy regimen in children less than 5 years of age
研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to evaluate the efficacy of the combination of surgery, conventional chemotherapy, sequential high-dose chemotherapy with peripheral blood stem cell transplantation and reduced dose radiation therapy in high-risk PNET brain tumors.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
— 至 10 Years（Child）
性别
All
接受健康志愿者
否

入选标准

  • •Medulloblastoma in patients less than 5 years of age
  • •Brain PNET in patients less than 10 years of age
  • •Histologically documented diagnosis
  • •Body weight of > 8 kg

排除标准

  • •Parents' refusal

结局指标

主要结局

Response of medulloblastoma metastases to the chemotherapy regimen in children less than 5 years of age

Progression-free survival of children less than 10 years of age with brain PNET

次要结局

  • Progression-free survival of children less than 5 years of age with metastatic medulloblastoma
  • Toxicity
  • Long term sequelae

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验

Unknown
2 期
Response-based Treatment of High-risk NeuroblastomaNewly Diagnosed High Risk Neuroblastoma
NCT02771743Samsung Medical Center54
已完成
不适用
Comparison of Standard Neuronavigation With Intraoperative Magnetic Resonance Imaging (MRI) for the Neurosurgical Treatment of Malignant Brain TumorsGlioblastoma Multiforme
NCT00943007Maastricht University Medical Center14
招募中
2 期
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOAAnaplastic AstrocytomaAnaplastic OligoastrocytomaBrain NeoplasmBrain CancerBrain Tumor, RecurrentBrain Neoplasm, MalignantGlioblastomaGliomaBrain Tumor
NCT02800486Northwell Health37
招募中
不适用
Response-based treatment of high-risk neuroblastomaNeoplasms
KCT0002038Samsung Medical Center54
进行中（未招募）
2 期
Surgical Pembro +/- Olaparib w TMZ for rGBMGlioblastomaRecurrent Glioblastoma
NCT05463848L. Nicolas Gonzalez Castro, MD, PhD52